EKF receives FDA clearance and CLIA waiver for reagent-free hemoglobin analyzer

Easy to use, reagent-free analyzer cleared for use in POC & CLIA waived settings

EKF Diagnostics, the global in vitro diagnostics company, announces U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waiver for the Company’s hand-held, reagent-free hemoglobin analyzer, the DiaSpect Tm. The device is cleared for use in point of care (POC) and Certificate of Waiver settings, such as physicians’ offices, clinics and other non-traditional laboratory locations.

The hand-held DiaSpect Tm enables reagent-free hemoglobin analysis within two seconds.
The hand-held DiaSpect Tm enables reagent-free hemoglobin analysis within two seconds. Image credit: EKF Diagnostics

The DiaSpect Tm provides users with accurate hemoglobin measurements (precision: CV ≤1%) within two seconds of its whole blood-filled cuvette being inserted for analysis. This ensures immediate and robust hemoglobin results for patient health checks and anemia screening at the point of care.

Based on its FDA categorization, DiaSpect Tm can be used in a variety of settings, as well as by a wide range of health care personnel. Essential for this, it is highly user-friendly requiring minimal training. The user simply collects a capillary or venous blood sample of 10 µL in the cuvette before inserting straight into the analyzer. Also making it simple for POCT use, DiaSpect Tm is factory calibrated against the HiCN reference method in accordance with ICSH. It is ‘always on’ and ready to use with no re-calibration or maintenance necessary.

Commenting, Julian Baines, CEO of EKF Diagnostics, said:

The FDA clearance of DiaSpect Tm is part of our overall strategy to widen the range of regulatory approvals for our existing product range and to drive sales growth for these products across additional geographies. The US market is a key target for our DiaSpect Tm product, where we see a significant need for an easy to use, accurate and portable hemoglobin measurement system that can deliver laboratory quality results to patients in the clinic within seconds.

FDA clearance is also a mark of the quality and reliability of a device which is recognized and trusted around the world. Lightweight and palm-sized, DiaSpect Tm is ideal for POCT in remote situations, not only due to its portability and unmatched measurement speed, but also through its rechargeable internal battery. This provides up to 40 days/10,000 tests continuous use, giving the flexibility of not needing a power source for weeks at a time.

DiaSpect’s reagent-free cuvettes have up to 2.5 years shelf life, even after opening, and are unaffected by temperature or humidity. These disposable cuvettes can be stored from 0 to 50°C, meaning temperature-controlled storage is not necessary - short term storage is even possible at -30°C to 70°C for 24 hours. This all makes the device highly suited for hemoglobin testing in a range of locations, environments and climatic conditions.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EKF Diagnostics. (2020, May 12). EKF receives FDA clearance and CLIA waiver for reagent-free hemoglobin analyzer. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20180502/EKF-receives-FDA-clearance-and-CLIA-waiver-for-reagent-free-hemoglobin-analyzer.aspx.

  • MLA

    EKF Diagnostics. "EKF receives FDA clearance and CLIA waiver for reagent-free hemoglobin analyzer". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20180502/EKF-receives-FDA-clearance-and-CLIA-waiver-for-reagent-free-hemoglobin-analyzer.aspx>.

  • Chicago

    EKF Diagnostics. "EKF receives FDA clearance and CLIA waiver for reagent-free hemoglobin analyzer". News-Medical. https://www.news-medical.net/news/20180502/EKF-receives-FDA-clearance-and-CLIA-waiver-for-reagent-free-hemoglobin-analyzer.aspx. (accessed April 25, 2024).

  • Harvard

    EKF Diagnostics. 2020. EKF receives FDA clearance and CLIA waiver for reagent-free hemoglobin analyzer. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20180502/EKF-receives-FDA-clearance-and-CLIA-waiver-for-reagent-free-hemoglobin-analyzer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
EKF Diagnostics appoints Luke Daum as Chief Scientific Officer